Skip to content

Deferred registration: Quotient Sciences Code: QSC302976

Deferred registration: Quotient Sciences code: QSC302976 [Full scientific title to be added on or before the deferral expiry date]

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN17799325
Enrollment
8
Registered
2026-07-03
Start date
2026-08-11
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers Other

Interventions

Sponsors

Epygenix Therapeutics, Inc.
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Exclusion criteria

Exclusion criteria: This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Design outcomes

Primary

MeasureTime frame
[Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

Countries

England, United Kingdom

Contacts

Public ContactRobert Faulkner
rfaulkner@harmonybiosciences.com+1 817-773-1958

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 25, 2026